United Therapeutics (UTHR) Short-Term Debt repayments (2014 - 2025)

United Therapeutics has disclosed Short-Term Debt repayments across 7 years of filings, most recently posting $400.0 million for Q2 2025.

• Short-Term Debt repayments for Q2 2025 came in at $400.0 million, up 300.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $400.0 million (changed 0.0% YoY), and the FY2025 annual result was $500.0 million, up 25.0% from the prior year.
• Short-Term Debt repayments came in at $400.0 million for Q2 2025 at United Therapeutics, up from $100.0 million in the prior quarter.
• In the past five years, Short-Term Debt repayments ranged from a high of $800.0 million in Q1 2022 to a low of $100.0 million in Q4 2023.
• The 4-year median for Short-Term Debt repayments is $100.0 million (2023), against an average of $225.0 million.
• Across the five-year window, Short-Term Debt repayments changed 0.0% in 2024 and jumped 300.0% in 2025, its largest moves.
• United Therapeutics' Short-Term Debt repayments stood at $800.0 million in 2022, then tumbled by 87.5% to $100.0 million in 2023, then changed by 0.0% to $100.0 million in 2024, then surged by 300.0% to $400.0 million in 2025.
• The last three Short-Term Debt repayments figures came in at $400.0 million (Q2 2025), $100.0 million (Q1 2025), and $100.0 million (Q4 2024), per Business Quant data.